drugset / Trial / NCT05869955
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
Phase 1
Recruiting
270 enrolled
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Bristol-Myers Squibb Services Unlimited Company · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to establish the tolerability, preliminary efficacy, and pharmacokinetics of CC-97540 in participants with severe, refractory autoimmune diseases (Breakfree-1).
Timeline
- Start
- 2023-09-13
- Primary completion
- 2028-08-29
- Completion
- 2028-08-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zolacabtagene- Autoleucel | Cell therapy | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |
| Background | Tocilizumab | Monoclonal antibody | — | — |